Literature DB >> 25662807

A preliminary study on a new model system to evaluate tumour-detection and tumour-purging protocols in ovarian cortex tissue intended for fertility preservation.

R Peek1, L Bastings2, J R Westphal2, L F A G Massuger2, D D M Braat2, C C M Beerendonk2.   

Abstract

STUDY QUESTION: Is it possible to create a model system that mimics ovarian metastatic disease in order to devise new strategies to detect cancer cells and prevent cancer cell transmission via ovarian tissue autotransplantation in cancer survivors? SUMMARY ANSWER: Injection of bovine or human ovarian cortex fragments with cells from different cancer types led to the formation of proliferating tumour masses and newly formed small metastatic lesions. WHAT IS KNOWN ALREADY: Autotransplantation of ovarian tissue comes with the major concern of cancer cells possibly being present in the tissue. A model system to develop strategies aimed at enhancing the safety of ovarian tissue autotransplantation is currently lacking. STUDY DESIGN, SIZE, DURATION: The ability of injected human leukaemia, lymphoma, Ewing's sarcoma or breast cancer cells to proliferate and form tumour-like structures in bovine and human ovarian cortex tissue in vitro was assessed. The injected cells were from human cancer cell lines. After 4 days of culture, some tissue fragments were harvested for standard histological staining and immunohistochemical staining of tumour cell specific antigens and the Ki67 proliferation marker, while the remaining fragments were incubated for an additional 6 days (bovine tissue) or 3 days (human tissue) before analysis. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Experiments were performed with ovarian tissue from women after prophylactic salpingo-oophorectomy. Bovine ovarian tissue was obtained at an abattoir. Glucose uptake during in vitro culture was monitored to quantify the viability of tissue. Tumour formation was assessed at Day 4 and Day 10 in bovine ovarian tissue and at Day 4 and Day 7 in human ovarian tissue, using histology and immunohistochemistry. MAIN RESULTS AND THE ROLE OF CHANCE: We found that bovine and human ovarian cortex tissue could be cultured for up to 10 and 7 days, respectively, without any loss of viability. Our preliminary results show that all cell lines tested were capable of forming proliferating tumours in ovarian cortex tissue in vitro. Lymphoma and breast cancer cells produced small metastases near the original lesions. LIMITATIONS, REASONS FOR CAUTION: The tumour model presented was based on the growth of human cancer cell lines in ovarian cortex tissue. It is unknown whether these cells behave differently from malignant cells derived from primary tumours. In addition, the human ovarian tissue was derived from women over 39 years of age, which is obviously considerably older than patients opting for ovarian tissue cryopreservation. WIDER IMPLICATIONS OF THE
FINDINGS: Our model system will facilitate the development of procedures to detect cancer cells in, or purge cancer cells from, human ovarian tissue. STUDY FUNDING/COMPETING INTERESTS: Unconditional funding was received from the Radboud Institute for Health Sciences, KiKa Foundation and Merck Serono. There are no conflicts of interest to declare.
© The Author 2015. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cancer; fertility preservation; ovarian tissue; purging; safety

Mesh:

Substances:

Year:  2015        PMID: 25662807     DOI: 10.1093/humrep/dev013

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

Review 1.  Vitrification of embryos and oocytes for fertility preservation in cancer patients.

Authors:  Keiichi Kato
Journal:  Reprod Med Biol       Date:  2016-02-29

2.  An ovarian bioreactor for in vitro culture of the whole bovine ovary: a preliminary report.

Authors:  Matthew R Zanotelli; Joseph D Henningsen; Patrick M Hopkins; Aaron P Dederich; Tessa Herman; Tracy J Puccinelli; Sana M Salih
Journal:  J Ovarian Res       Date:  2016-08-04       Impact factor: 4.234

3.  Complete protection against cryodamage of cryopreserved whole bovine and human ovaries using DMSO as a cryoprotectant.

Authors:  Johan R Westphal; Renne Gerritse; Didi D M Braat; Catharina C M Beerendonk; Ronald Peek
Journal:  J Assist Reprod Genet       Date:  2017-06-03       Impact factor: 3.412

4.  Ovarian follicles of young patients with Turner's syndrome contain normal oocytes but monosomic 45,X granulosa cells.

Authors:  Ronald Peek; Myra Schleedoorn; Dominique Smeets; Guillaume van de Zande; Freek Groenman; Didi Braat; Janielle van der Velden; Kathrin Fleischer
Journal:  Hum Reprod       Date:  2019-09-29       Impact factor: 6.918

Review 5.  Current state and future possibilities of ovarian tissue transplantation.

Authors:  Seido Takae; Nao Suzuki
Journal:  Reprod Med Biol       Date:  2019-04-08

6.  A multi-centre, retrospective case series of oocyte cryopreservation in unmarried women diagnosed with haematological malignancies.

Authors:  K Kato; M Ochi; Y Nakamura; H Kamiya; T Utsunomiya; K Yano; Y Michikura; T Hara; K Kyono; K Takeuchi; T Nakayama; J Iwamasa; Y Mio; T Kuramoto; Y Nagata; T Jo; Y Asada; H Ohishi; H Osada; H Yoshida
Journal:  Hum Reprod Open       Date:  2021-01-16

7.  Why Turner patients with 45, X monosomy should not be excluded from fertility preservation services.

Authors:  M J Schleedoorn; K Fleischer; Ddm Braat; Ajm Oerlemans; Aaem van der Velden; R Peek
Journal:  Reprod Biol Endocrinol       Date:  2022-09-22       Impact factor: 4.982

8.  Purging human ovarian cortex of contaminating leukaemic cells by targeting the mitotic catastrophe signalling pathway.

Authors:  Lotte Eijkenboom; Callista Mulder; Bert van der Reijden; Norah van Mello; Julia van Leersum; Thessa Koorenhof-Scheele; Didi Braat; Catharina Beerendonk; Ronald Peek
Journal:  J Assist Reprod Genet       Date:  2021-03-16       Impact factor: 3.412

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.